ACM
EVOK

AIGH Capital Management’s Evoke Pharma EVOK Stock Holding History

AIGH Capital Management’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-70,546
Closed -$339K – 41
2024
Q3 		$339K Sell
70,546
-1
-0% -$5 0.1% 39
2024
Q2 		$448K Hold
70,547
– – 0.14% 37
2024
Q1 		$516K Buy
+70,547
New +$599K 0.16% 40
2021
Q4 		– Sell
-11,814
Closed -$2.21M – 58
2021
Q3 		$2.21M Hold
11,814
– – 0.47% 39
2021
Q2 		$2.33M Buy
11,814
+1,862
+19% +$399K 0.42% 40
2021
Q1 		$2.62M Buy
+9,952
New +$3.98M 0.55% 38

Other funds holding EVOK

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AIGH Capital Management's EVOK Position: Q4 2024 in Review

AIGH Capital Management sold out of Evoke Pharma (EVOK) in Q4 2024, closing a stake of 70,546 shares — an estimated $339K sold.

AIGH Capital Management first reported a position in EVOK in Q1 2021 and held it in 6 quarters. The position peaked at $2.62M in Q1 2021. 8 funds tracked by Wall St. Rank hold EVOK as of Q4 2024.

  • AIGH Capital Management reported no remaining Evoke Pharma position as of Q4 2024 after selling out during the quarter.
  • AIGH Capital Management sold 70,546 Evoke Pharma shares in Q4 2024, an estimated $339K.
  • AIGH Capital Management first reported a position in Evoke Pharma in Q1 2021 and held it in 6 quarters.
  • AIGH Capital Management's Evoke Pharma position peaked at $2.62M in Q1 2021.
  • 8 funds tracked by Wall St. Rank held Evoke Pharma as of Q4 2024.

Based on AIGH Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.